Health Canada is currently evaluating nine submissions for generic versions of popular weight loss medications that could potentially reduce costs, according to pharmaceutical experts. These submissions involve generic forms of semaglutide, the active ingredient in Novo Nordisk’s injectable prescription drugs Ozempic and Wegovy, both approved by Health Canada for diabetes and weight loss. Semaglutide belongs to the GLP-1 therapy class, mimicking a natural gut hormone to regulate blood sugar, slow digestion, and enhance feelings of fullness. Common side effects may include nausea, vomiting, diarrhea, stomach pain, fatigue, constipation, and headaches.
Canada holds a unique position as the only country where Novo Nordisk’s patent for semaglutide drugs has expired, leading to the end of “regulatory exclusivity” on January 4. Consequently, Canada is poised to potentially offer a more affordable alternative to Ozempic and Wegovy, though immediate availability is uncertain. Health Canada and Novo Nordisk have not confirmed the timeline for introducing a Wegovy pill in Canada.
Generics are considered equivalent to brand-name drugs by Health Canada, subject to rigorous safety, quality, and effectiveness criteria. The evaluation process for generic semaglutide drugs is intricate due to the initial biological development of semaglutide compared to simpler chemical production for generics. Pricing for generics depends on various factors such as formulation, dosing, and market competition, impacting accessibility and affordability for patients.
Experts anticipate that the introduction of cheaper generic alternatives may not occur immediately, with potential availability projected for the summer rather than early in the year. The move towards generic versions could significantly lower costs, benefitting Canadians currently paying substantial amounts for GLP-1 medications out-of-pocket. Accessibility for patients without insurance coverage is highlighted as a crucial aspect, particularly as obesity affects a significant portion of the population.
Companies like Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada have submitted generic versions for Health Canada’s review. Not all company names are disclosed due to policy changes as of April 1, 2023, requiring sponsors to be identified in submissions.